A microRNA screen to identify modulators of sensitivity to BCL2 inhibitor ABT-263 (navitoclax).

@article{Lam2010AMS,
  title={A microRNA screen to identify modulators of sensitivity to BCL2 inhibitor ABT-263 (navitoclax).},
  author={Lloyd T Lam and Xin Lu and Haichao Zhang and Rick Lesniewski and Saul Rosenberg and Dimitri Semizarov},
  journal={Molecular cancer therapeutics},
  year={2010},
  volume={9 11},
  pages={2943-50}
}
Evasion of apoptosis is a known feature of cancer cells. One mechanism of deregulating the apoptotic pathway is through overexpression of antiapoptotic BCL2 family members. ABT-263 (navitoclax) is a first-in-class BCL2 family inhibitor that restores the ability of cancer cells to undergo apoptosis. However, many cancer cells are resistant to ABT-263 due to high levels of a BCL2 family member, MCL1, which is not targeted by the drug. MCL1 expression is regulated transcriptionally… CONTINUE READING

From This Paper

Topics from this paper.
24 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 24 extracted citations

Similar Papers

Loading similar papers…